Corvus Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
CRVS$11.35+7.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| · · · · | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Exhibit · · · · Incorporated by Reference · · Filed | ||||||||||
| Number · Exhibit Description · Form · Date · Number · Herewith | ||||||||||
| | | | | | | | | | | |
| 3.1 | | Amended and Restated Certificate of Incorporation. | | 8-K | | 3/29/2016 | | 3.1 | | |
| | | | | | | | | | | |
| 3.2 | | Amended and Restated Bylaws. | | 8-K | | 3/29/2016 | | 3.2 | | |
| | | | | | | | | | | |
| 31.1 | | Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a). | | | | | | | | X |
| | | | | | | | | | | |
| 31.2 | | Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a). | | | | | | | | X |
| | | | | | | | | | | |
| 32.1* | | Certification required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350). | | | | | | | | X |
| | | | | | | | | | | |
| 101.INS | | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | | | | | | | | X |
| | | | | | | | | | | |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document. | | | | | | | | X |
| | | | | | | | | | | |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | | | | | | | | X |
| | | | | | | | | | | |
| 101.DEF | | Inline XBRL Taxonomy Extension Definitions Linkbase Document. | | | | | | | | X |
| | | | | | | | | | | |
| 101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document. | | | | | | | | X |
| | | | | | | | | | | |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | | | | | | | | X |
| | | | | | | | | | | |
| 104 | | The cover page of Corvus Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the three months ended September 30, 2025, formatted in Inline XBRL (contained in Exhibit 101). | | | | | | | | X |
| * | The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.